Steven P. Balk

Beth Israel Deaconess Medical Center — United States

Medicine · Health Sciences

91h-index30.5kcitations726works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(462), Hormonal and reproductive studies(133), Cancer, Lipids, and Metabolism(130), Immune Cell Function and Interaction(105), Estrogen and related hormone effects(91)

Publications724 total

Supplementary Data from WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth
2025Open Access
Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Figures S1-S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
2025Open Access
Supplementary Data from LSD1 Inhibition Disrupts Super-Enhancer–Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer
2025Open Access
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
iScience·2025Open Access
Supplementary Table 1 from Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Table 2 from Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
2025Open Access
Data from Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Methods 1 from Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
2025Open Access
Supplementary Figures 1 from Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
2025Open Access
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Nature Communications·2025· 2 citedOpen Access
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer
Molecular Cancer Therapeutics·2025· 2 cited
page 1 of 37Next →

Frequent Co-authors

Glenn J. Bubley(11), Mark A. Exley(11), Changmeng Cai(8), Xin Yuan(7), Massimo Loda(6), Philip W. Kantoff(6), Myles Brown(6), Steven A. Porcelli(6), Peter S. Nelson(6), Housheng Hansen He(5), Sen Chen(5), Adam G. Sowalsky(5), Richard S. Blumberg(5), Mary‐Ellen Taplin(4), Hongyun Wang(4), Lawrence D. True(4), Cox Terhorst(4), Shaoyong Chen(4), Huihui Ye(4), Qianben Wang(3)